A Director at Corcept Therapeutics Inc (NASDAQ: CORT) is Selling SharesBy Carrie Williams
Over the last month, Patrick Enright has reported another 3 Sell trades on CORT for a total of $35.43M. In addition to Patrick Enright, 2 other CORT executives reported Sell trades in the last month.
Based on Corcept Therapeutics Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $23.81 million and quarterly net profit of $4.6 million. In comparison, last year the company earned revenue of $14.97 million and had a net profit of $959K. The company has a one year high of $11.40 and a one year low of $4.09. CORT’s market cap is $1.12B and the company has a P/E ratio of 141.83.
Three different firms, including BMO Capital and Merrill Lynch, currently also have a Sell rating on the stock.
The insider sentiment on Corcept Therapeutics Inc has been negative according to 21 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Patrick Enright’s trades have generated a 15.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff On May 13, 1998 by and is headquartered in Menlo Park, CA.